Ras oncogene-induced sensitization to 1-β-D-arabinofuranosylcytosine

Cancer Research

Volumn 59, Issue 24, 1999, Pages 6057-6062

  Koo, Han Mo ^a   McWilliams, Mary Jane ^a   Alvord, W Gregory ^b   Vande Woude, George F ^c,d  

^a ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^b Data Management Services Inc   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DEOXYCYTIDINE;

APOPTOSIS; ARTICLE; CELL CYCLE S PHASE; CYTOTOXICITY; GENE ACTIVATION; HUMAN; HUMAN CELL; ONCOGENE RAS; PRIORITY JOURNAL; SENSITIZATION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; CYTARABINE; DEOXYCYTIDINE KINASE; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; GENES, RAS; HUMANS; S PHASE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033572310     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Rohatiner, A. Z. S., and Lister, T. A. The treatment of acute myelogenous leukemia. In: E. S. Henderson and T. A. Lister (eds.), Leukemia, 5th ed., pp. 485-514. Philadelphia: W. B. Saunders Co., 1990.
2. Rustum, Y. M., and Raymakers, R. A. 1-β-Arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview. Pharmacol. Ther., 56: 307-321, 1992.
3. Grant, S. Ara-C. Cellular and molecular pharmacology. In: G. F. V. Woude and G. Klein (eds.), Advances in Cancer Research, Vol. 72, pp. 195-233, San Diego, CA: Academic Press, 1998.
4. Kufe, D. W., and Spriggs, D. R. Biochemical and cellular pharmacology of 1-β-D-arabinofuranosylcytosine. Semin. Oncol., 12: 34-48, 1985.
5. Mesner, J. P. W., Budihardjo, I. I., and Kaufmann, S. H. Chemotherapy-induced apoptosis. Adv. Pharmacol., 41: 461-498, 1997.
6. Bos, J. L. ras Oncogenes in human cancer: A review. Cancer Res., 49: 4682-4689, 1989.
7. Barbacid, M. ras Oncogenes: Their role in neoplasia. Eur. J. Clin. Invest., 20: 225-235, 1990.
8. Koo, H-M., Monks, A., Mikheev, A., Rubinstein, L. V., Gray-Goodrich, M., McWilliams, M. J., Alvord, W. G., Oie, H. K., Gazdar, A. F., Paull, K. D., Zarbl, H., and Vande Woude, G. F. Enhanced sensitivity to 1-β-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras Oncogenes. Cancer Res., 56: 5211-5216, 1996.
9. Koo, H-M., Gray-Goodrich, M., Kohlhagen, G., McWilliams, M. J., Jeffers, M., Vaigro-Wolff, A., Alvord, W. G., Monks, A., Paull, K. D., Pommier, Y., and Vande Woude, G. F. The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis. J. Natl. Cancer Inst., 91: 236-244, 1999.
10. Neubauer, A., Dodge, R. K., George, S. L., Davey, F. R., Silver, R. T., Schiffer, C. A., Mayer, R. J., Ball, E. D., Wurster-Hill, D., Bloomfield, C. D., and Liu, E. T. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood. 83: 1603-1611, 1994.
11. Coghlan, D. W., Morley, A. A., Matthews, J. P., and Bishop, J. F. The incidence and prognostic significance of mutations in codon 13 of the N-ras gene in acute myeloid leukemia. Leukemia, 8: 1682-1687, 1994.
12. Liu, E. T., Dodge, R., Meyer, A., Zhang, X. X., Schiffer, C., Mayer, R., and Bloomfield, C. D. De nova acute myeloid leukemias harboring ras mutations exhibit preferential sensitivity to dose intensive cytarabine as consolidation therapy. Blood, 86: 2380, 1995.
13. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., Gray-Goodrich, M., Campbell, H., Mayo, J., and Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer. Inst., 83: 757-766, 1991.
14. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997.
15. Filmus, J., Robles, A. I., Shi, W., Wong, M. J., Colombo, L. L., and Conti, C. J. Induction of cyclin D1 overexpression by activated ras. Oncogene, 9: 3627-3633. 1994.
16. Winston, J. T., Coats, S. R., Wang, Y-Z., and Pledger, W. J. Regulation of the cell cycle machinery by oncogenic ras. Oncogene, 12: 127-134, 1996.
17. Leone, G., DeGregori, J., Sears, R., Jakoi, L., and Nevins, J. R. Myc and ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature (Lond.), 387: 422-426, 1997.
18. Wang, L-M., White, J. C., and Capizzi, R. L. The effect of ara-C-induced inhibition of DNA synthesis on its cellular pharmacology. Cancer Chemother. Pharmacol., 25: 418-424, 1990.
19. Weinert, T., and Lydall, D. Cell cycle checkpoints, genetic instability and cancer. Semin. Cancer Biol., 4: 129-140, 1993.
20. Meikrantz, W., Gisselbrecht, S., Tam, S. W., and Schlegel, R. Activation of cyclin A-dependent protein kinases during apoptosis. Proc. Natl. Acad. Sci. USA, 91: 3754-3758, 1994.
21. Hoang, A. T., Cohen, K. J., Barrett, J. F., Bergstrom, D. A., and Dang, C. V. Participation of cyclin A in Myc-induced apoptosis. Proc. Natl. Acad. Sci. USA, 91: 6875-6879, 1994.
22. Bortner, D. M., and Rosenberg, M. P. Overexpression of cyclin A in the mammary glands of transgenic mice results in the induction of nuclear abnormalities and increased apoptosis. Cell Growth & Differ., 6: 1579-1589, 1995.
23. Meikrantz, W., and Schlegel, R. Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases. J. Biol. Chem., 271: 10205-10209. 1996.